LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial

Paul Nathan, Reinhard Dummer, Georgina V. Long, Paolo A. Ascierto, Hussain Tawbi, Caroline Robert, Piotr Rutkowski, О. В. Леонов, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Keith T. Flaherty, Jan C. Brase, S. Green, T Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf